530 related articles for article (PubMed ID: 11307780)
1. [The promise of statins].
Capurso A
Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
[TBL] [Abstract][Full Text] [Related]
2. [New information on the pathophysiology of atherosclerosis].
Reiner Z; Tedeschi-Reiner E
Lijec Vjesn; 2001; 123(1-2):26-31. PubMed ID: 11379194
[TBL] [Abstract][Full Text] [Related]
3. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
4. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)].
Igel M; Sudhop T; von Bergmann K
Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244
[TBL] [Abstract][Full Text] [Related]
5. Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept.
van der Wal AC; Becker AE; van der Loos CM; Tigges AJ; Das PK
Coron Artery Dis; 1994 Jun; 5(6):463-9. PubMed ID: 7952404
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W; Köenig W
J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
[TBL] [Abstract][Full Text] [Related]
7. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
8. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
Gmiński J; Wojakowski W
Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
[TBL] [Abstract][Full Text] [Related]
9. [Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared].
Kostner KM; Kostner GM
Wien Klin Wochenschr; 1998 Oct; 110(18):625-30. PubMed ID: 9816634
[TBL] [Abstract][Full Text] [Related]
10. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
Cevik C; Otahbachi M; Nugent K; Warangkana C; Meyerrose G
J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1274-8. PubMed ID: 19001938
[TBL] [Abstract][Full Text] [Related]
11. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Luan Z; Chase AJ; Newby AC
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
[TBL] [Abstract][Full Text] [Related]
12. [Immune factors in atherosclerosis].
Pasqui AL; Bova G; Maffei S; Auteri A
Ann Ital Med Int; 2005; 20(2):81-9. PubMed ID: 16052840
[TBL] [Abstract][Full Text] [Related]
13. [Statins: possibly more than just lowering of the lipid level].
Visseren FL; Lansberg PJ; Erkelens DW; Kastelein JJ
Ned Tijdschr Geneeskd; 2000 Feb; 144(7):316-21. PubMed ID: 10707742
[TBL] [Abstract][Full Text] [Related]
14. Statins effect on smooth muscle cell proliferation.
Bellosta S; Arnaboldi L; Gerosa L; Canavesi M; Parente R; Baetta R; Paoletti R; Corsini A
Semin Vasc Med; 2004 Nov; 4(4):347-56. PubMed ID: 15861311
[TBL] [Abstract][Full Text] [Related]
15. Statins, super-statins and cholesterol absorption inhibitors.
Brousseau ME
IDrugs; 2003 May; 6(5):458-63. PubMed ID: 12789600
[TBL] [Abstract][Full Text] [Related]
16. [Statins and their influence on inflammatory processes in internal carotid artery stenosis].
Kunte H; Amberger N; Rückert RI; Harms L
Zentralbl Chir; 2007 Jun; 132(3):193-7. PubMed ID: 17610188
[TBL] [Abstract][Full Text] [Related]
17. The new "lower is better" lipid goals: are they achievable with today's drugs?
Chilton RJ
J Am Osteopath Assoc; 2002 May; 102(5 Suppl 1):S1-5. PubMed ID: 12046679
[TBL] [Abstract][Full Text] [Related]
18. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects and cholesterol-lowering therapy.
Shaw SM; Fildes JE; Yonan N; Williams SG
Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
[TBL] [Abstract][Full Text] [Related]
20. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
